Church James A, Chasekwa Bernard, Rukobo Sandra, Govha Margaret, Lee Benjamin, Carmolli Marya P, Ntozini Robert, Mutasa Kuda, McNeal Monica M, Majo Florence D, Tavengwa Naume V, Kirkpatrick Beth D, Moulton Lawrence H, Humphrey Jean H, Prendergast Andrew J
Zvitambo Institute for Maternal and Child Health Research, Harare, Zimbabwe; Centre for Genomics & Child Health, Blizard Institute, Queen Mary University of London, UK.
Zvitambo Institute for Maternal and Child Health Research, Harare, Zimbabwe.
Vaccine. 2020 Mar 17;38(13):2870-2878. doi: 10.1016/j.vaccine.2020.01.097. Epub 2020 Feb 19.
Oral rotavirus vaccines (RVV) have poor immunogenicity in low-income countries, for reasons that remain unclear. This study identified the determinants of RVV immunogenicity among infants in rural Zimbabwe.
Anti-rotavirus IgA titres were measured among a sub-group of infants enrolled in the Sanitation Hygiene Infant Nutrition Efficacy (SHINE) trial (NCT01824940). SHINE was a cluster-randomized trial of improved infant and young child feeding, and improved water, sanitation and hygiene (WASH) in two rural Zimbabwean districts. Infants received RVV as part of the national immunisation programme. Among HIV-unexposed infants in the non-WASH trial arms, we evaluated associations between potential risk factors (vaccine schedule and dose, maternal and infant nutritional status, infant diarrhoea, and household environment) and RVV immunogenicity (seroconversion, seropositivity and geometric mean titres) using multivariable regression.
Among 219 infants with seroconversion data, 43 (20%) successfully seroconverted and 176 (80%) failed to seroconvert to RVV. Seroconversion was positively associated with a higher length-for-age Z-score (LAZ) around the time of vaccination (adjusted RR 1.27 (95% CI 1.04, 1.55), P = 0.021), and negatively associated with concurrent OPV and RVV administration (adjusted RR 0.36 (0.19, 0.71), P = 0.003). Among 472 infants with post-vaccination titres, a higher LAZ score was associated with increased seropositivity (aRR 1.21 (95% CI 1.06, 1.38), P = 0.004), and higher birthweight was associated with increased IgA titres (0.45 (95%CI 0.18, 1.09) U/mL greater per 100 g gain in birthweight; P = 0.001).
Infant ponderal and linear growth were positively associated with RVV immunogenicity, while concurrent administration of OPV was negatively associated with RVV immunogenicity. Together, these findings suggest that improving foetal growth and separating RVV and OPV administration are plausible approaches to increasing RVV immunogenicity.
口服轮状病毒疫苗(RVV)在低收入国家免疫原性较差,原因尚不清楚。本研究确定了津巴布韦农村地区婴儿RVV免疫原性的决定因素。
在参与环境卫生、婴儿营养功效(SHINE)试验(NCT01824940)的一组婴儿中测量抗轮状病毒IgA滴度。SHINE是一项在津巴布韦两个农村地区进行的关于改善婴幼儿喂养以及改善水、环境卫生和个人卫生(WASH)的整群随机试验。婴儿作为国家免疫规划的一部分接种RVV。在非WASH试验组中未接触过HIV的婴儿中,我们使用多变量回归评估了潜在风险因素(疫苗接种程序和剂量、母婴营养状况、婴儿腹泻和家庭环境)与RVV免疫原性(血清转化、血清阳性和几何平均滴度)之间的关联。
在219名有血清转化数据的婴儿中,43名(20%)成功实现血清转化,176名(80%)未实现RVV血清转化。血清转化与接种疫苗时较高的年龄别身长Z评分(LAZ)呈正相关(调整后RR 1.27(95%CI 1.04,1.55),P = 0.021),与同时接种口服脊髓灰质炎疫苗(OPV)和RVV呈负相关(调整后RR 0.36(0.19,0.71),P = 0.003)。在472名接种疫苗后有滴度数据的婴儿中,较高的LAZ评分与血清阳性增加相关(调整后RR 1.21(95%CI 1.06,1.38),P = 除了调整后的RR 0.45(95%CI 0.18,1.09)U/mL(出生体重每增加100 g),P = 0.001)。
婴儿的体重和线性生长与RVV免疫原性呈正相关,而同时接种OPV与RVV免疫原性呈负相关。总之,这些发现表明改善胎儿生长以及分开接种RVV和OPV是提高RVV免疫原性的可行方法。